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S  Optic pathway gliomas represent approximately 3-5% of childhood intracranial tumors. They usually occur in chil­
dren during the first decade of life and are seen in 11-30% of patients with neurofibromatosis Type 1 (NF1). Although 
these tumors are typically low-grade gliomas, the clinical course and natural history are highly variable, making treat­
ment paradigms difficult. Overall, however, they are often indolent tumors that can be observed over time for pro­
gression without initial treatment, especially in patients with NF1. Chemotherapy is the first-line treatment for pro­
gressive tumors, and radiation therapy is reserved for patients with progressive disease who are older than 5-7  years. 
Surgery is reserved for large tumors causing mass effect or hydrocephalus and tumors confined to the orbit or unilat­
eral optic nerve. (DOI: 10.3171/FOC-07/11/E2)
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O p t ic  pathway gliomas represent approximately 3­
5% of childhood brain tumors111215'25'28'33'35'74'75'83 and 
affect 11-30% of children with NF1.3'28'48^ '64'75'79 
When associated with NF1, the tumors are more often 
benign, can be multifocal and bilateral,12,15 and are usually 
found within the optic nerves74,83 but can occur anywhere 
along the optic pathway, from the optic nerves to the visu­
al cortex.54 Chiasmatic gliomas are rarely associated with 
NF1, often have a more aggressive course, present with 
diencephalic syndrome (hypersomnia and cachexia), and 
typically progress.25,74,83 Overall, 25% of OPGs are confined 
to the optic disc and nerve, whereas 40-75% involve the 
chiasm. Of the tumors involving the chiasm, 33-60% are 
considered posterior lesions that also involve the hypothal­
amus or third ventricle.15,22,30,33 Approximately 75% of these 
tumors are diagnosed during the first decade of life and 
60% are diagnosed before the age of 5 years, which also 
portends a less favorable prognosis.2,29,33,74,83
One of the most complete reviews of all cases of OPG 
was published in 1994 by Dutton,15 who retrospectively 
reviewed all cases of OPG reported in the literature up to 
1992, which included 2297 patients. Of those patients, age
Abbreviations used in this paper: CSF = cerebrospinal fluid; CT = 
computed tomography; MR = magnetic resonance; NF1 = neurofi­
bromatosis Type 1; OPG = optic pathway glioma; PFS = progres­
sion-free survival.
data were available for 519 patients, and sex data were 
given for 594. The mean age at diagnosis was 8.8 years, 
although this included patients treated before the era of CT 
and MR imaging when diagnosis could be delayed. The 
mean age of diagnosis may be significantly lower, howev­
er, because of the advent and widespread use of CT and 
MR imaging. in addition, patients with OPGs that invade 
the hypothalamus typically present at a younger age (often 
by 1 year of age) with diencephalic syndrome.15,28 Although 
their occurrence in younger patients is more common, 
OPGs have been reported in patients up to 79 years of age.15 
The male-to-female predilection is roughly equal,15,29 al­
though there are some data that suggest that OPGs limited 
to the optic nerves are more common in girls.15 Although 
the incidence of OPGs in patients with NF1 is greater than 
that in the general population, not all patients with NF1 are 
screened for OPGs, and many OPGs can remain asympto­
matic. Therefore, the incidence of OPGs in the NF1 popu­
lation may, in fact, be underestimated.28
Presentation
Patients with OPG may be asymptomatic or may present 
with symptoms that vary depending on location. For in­
stance, patients with a tumor of the nerve within the orbit 
may have proptosis, strabismus, or visual loss, whereas pa­
tients with intracranial tumors can present with visual loss,
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endocrine/hypothalamic disturbance, spasmus nutans, and 
obstructive hydrocephalus.32848 In addition, Grill et al.23 
found that the presentation depended on whether the pa­
tient had NF1. In their series, proptosis was significantly 
more frequent in patients with NF1 (21.5%) than in those 
without (5.5%), whereas patients without NF1 were more 
likely to present with nystagmus and hydrocephalus. These 
authors also found that diencephalic syndrome was seen 
only in children younger than 4 years of age, whereas pre­
cocious puberty was seen only in patients older than 4 
years.
Overall, the most frequent clinical presentation of OPG 
is that of diminished vision and, in those cases in which 
tumor is confined to the optic nerve, proptosis.28 The NF1 
OPG Task Force recommends yearly eye examinations in 
children with asymptomatic NF1 through the age of 6 
years,3841-47,79 whereas other authors recommend screening 
up to 10 years of age.19 3441-47 This is true even in patients 
with NF1 and no findings on imaging studies, given that 
OPGs can become apparent even though previously ob­
tained images did not revealed any findings.53 In addition, 
because children may present with precocious puberty and 
accelerated linear growth, accurate growth charts are essen­
tial in patients with NF1.45
Monitoring of Visual Function
Patients with known OPGs are typically serially 
screened for progressive visual loss. Visual acuity is 
thought to be the most reliable test; however, in children 
younger than 6 years (the most common group to present 
with OPGs), this can be inaccurate. Visual evoked poten­
tials have also been used to evaluate OPG progression.5881 
Because visual evoked potentials measure the integrity of 
the visual pathway rather than actual visual function, how­
ever, they are difficult to interpret and are not recommend­
ed as a screening tool.45
Diagnostic Imaging
Diagnosis is confirmed with modern imaging. Although 
once the standard of care, biopsy of suspected lesions is no 
longer warranted for lesions with characteristic imaging 
features, and it is now used only in cases with unusual clin­
ical or imaging findings.4065 When imaging is not clearly 
indicative of OPG, biopsy may become a consideration 
for definitive diagnosis. The classic finding on plain radi­
ographs is enlargement of the optic canals and a J-shaped 
sella turcica. This is seen in 65-85% of patients with tumors 
of the optic nerves.18 When tumor is confined to the optic 
nerves, CT imaging demonstrates well-demarcated en­
largement of the nerve, often with a tortuous or kinked 
appearance of the nerves.15 65 Tumors of the chiasm exhibit 
a variety of appearances, from an enlargement of the chi­
asm to a suprasellar mass that may calcify.65 The tumor is 
usually isodense to brain, and contrast enhancement is 
variable.
Although OPGs may be readily apparent on CT scan­
ning, MR imaging is the preferred method of imaging. 
Typical MR imaging findings include the appearance of an 
iso- to hypointense lesion on T1-weighted images, with 
hyperintensity seen on T2-weighted sequences and homog-
F ig . 1. Magnetic resonance images obtained in a 19-month-old 
girl who presented with failure to thrive, visual loss, and horizon­
tal rotatory and pendular nystagmus from a biopsy-proven optic 
pathway juvenile pilocytic astrocytoma. Sagittal (A) and coronal 
(B) Gd-enhanced T1-weighted images. The patient was started on 
chemotherapy treatment. Follow-up sagittal (C) and coronal (D) 
T1-weighted Gd-enhanced images demonstrating decreased cen­
tral enhancement of the tumor and increased hydrocephalus requir­
ing a ventriculoperitoneal shunt to be placed on the left side. Two 
more courses of chemotherapy were administered. Follow-up 
sagittal (E) and coronal (F) images obtained 15 months post­
chemotherapy, showing a significant decrease in tumor size and 
minimal tumor enhancement with resolution of hydrocephalus.
eneous enhancement with Gd administration (Figs. 1-
3).15,28,68,72 Some authors have described detailed MR imag­
ing findings in patients with NF1, including bilateral 
tumors with circumferential growth and downward kinking 
of the intraorbital segment of the optic nerve.15 65 In addi­
tion, the double intensity or pseudo-CSF signal is charac­
teristic in NF1.15 65 This consists of a hyperintense core on 
T1-weighted images, surrounded by lower signal intensity. 
On T2-weighted images, the inverse is seen. Furthermore, 
patients with NF1 are more likely to demonstrate glioma 
extension along the optic tracts into the lateral geniculate 
ganglia and temporal lobes18,73 as well as infiltrating le- 
sions.25 Hydrocephalus may be apparent for large tumors 
that obstruct CSF outflow (Figs. 1 and 3).
Magnetic resonance imaging is also the modality of 
choice for monitoring progression or treatment response. 
Positron emission tomography technology has also been 
shown to be useful for monitoring progression and treat­
ment response in OPGs and may actually be found to 
change more quickly than MR imaging.64
Pathological Findings
Histologically, OPGs are typically low-grade gliomas; 
both pilocytic and fibrillary astrocytomas have been report­
ed,257483 although the majority of tumors are pilocytic.15 
Pilocytic astrocytomas classically have a biphasic pattern 
with characteristic Rosenthal fibers and eosinophilic gran­
ular bodies. In contrast, a relatively new subgroup of OPGs 
has been defined: pilomyxoid astrocytomas (Fig. 4). These 
tumors demonstrate piloid cells in a loose fibrillary and
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F ig . 2. Magnetic resonance images. Two years after the final 
images in Fig. 1 were obtained, the same patient presented with 
headaches and worsening vision. Sagittal (A) and coronal (B) 
T1-weighted Gd-enhanced images demonstrating recurrent tumor 
growth and enhancement obstructing the third ventricle resulting in 
unilateral right-sided hydrocephalus. A right frontal transcortical 
transventricular approach to the lateral and third ventricle was per­
formed. Tumor debulking was performed to open the CSF path­
ways, thus avoiding a second shunt placement (see Video Clip). 
Sagittal (C) and coronal (D) postoperative images showing re­
moval of the third ventricular portion of tumor and resolution of 
hydrocephalus. There is residual tumor in the optic apparatus and 
hypothalamus. [Click here for Windows and here for Real Player.]
myxoid background. They lack Rosenthal fibers and reveal 
only rare eosinophilic granular bodies.35 Pilomyxoid astro­
cytomas were once classified with pilocytic astrocytomas 
but are a distinct entity with more aggressive behavior.35,36 
In the series reported by Komotar et al.,35 14% of patients 
with pilomyxoid astrocytomas presented with CSF dissem­
ination, whereas no patients with pilocytic astrocytomas 
had CSF spread. The mean age at presentation for pilo- 
myxoid astrocytoma is also much younger (18 months).35 
Tumors can exhibit either a perineural or an intraneural 
growth pattern. Patients with NF1 are more likely to have a 
perineural pattern, whereas patients without NF1 predomi­
nantly have an intraneural growth pattern.15 Although in the 
past some authors advocated that OPGs are little more than 
hamartomatous growths of the optic nerves, this theory has 
fallen out of favor based on histological features, invasion, 
and ability to undergo malignant transformation.15 Enlarge­
ment is usually the result of cystic degeneration, hemorr­
hage, or accumulation of mucus.
Treatment of OPGs
The treatment of OPG is divided into observation, che­
motherapy, radiation therapy, and surgery. in patients who
are asymptomatic and have smaller tumors, careful obser­
vation may be considered. However, patients presenting 
with symptoms of visual loss, endocrine disturbance, hy­
drocephalus, or mass effect may require aggressive inter­
vention. Historically, radiation therapy was the treatment of 
choice for OPGs, but this modality has fallen out of favor 
as first-line therapy for OPGs in young children because of 
the cognitive and endocrine disturbances, as well as radia­
tion-induced complications such as secondary tumors and 
moyamoya disease in patients with NF1.9'14'32,70,71 Astrup5 
advocated observation for newly diagnosed OPG, resection 
for progressive intraorbital tumors, radiotherapy for pro­
gressive chiasmatic tumors in older children, and chemo­
therapy in children younger than 5 years. He also advocat­
ed surgery for some exophytic chiasmatic tumors.
Surgery fo r OPGs
The role of surgery in the treatment of OPG is contro­
versial. Complete tumor resection is only realistic when the 
tumor is limited to one optic nerve because the procedure 
causes blindness. Although surgical debulking of the tumor 
has not been found to affect overall survival, partial debulk- 
ing may be useful in some cases in which the tumor caus­
es mass effect or obstructive hydrocephalus. in the latter 
case, the goal of surgical debulking is to open up CSF path­
ways, thereby avoiding shunt placement (Fig. 2; see Video 
Clip). Therefore, contemporary indications for surgery in­
clude single nerve involvement causing progressive, dis­
figuring proptosis, blindness, or both, or exophytic chiasm 
tumors causing mass effect or hydrocephalus.2,5,54'55 Surgery 
is contraindicated in patients with infiltrative tumors. Al­
though authors of numerous case reports have described 
spontaneous regression of OPG after surgical debulking 
or biopsy without additional postoperative adjuvant thera-
py,25,28,54,55,84,85 it is unclear whether spontaneous regression
might have occurred without any treatment at all, which 
has also been well-reported.63,66 in 2006, Ahn et al.2 retro­
spectively reviewed a series of 33 patients with OPGs who 
had undergone surgery over a 17-year period. They found 
that radical removal of OPGs was of no survival benefit 
and that it did not reduce endocrine complications. They 
found it to be a benefit, however, in controlling hydroce­
phalus and in postponing radiation treatment in younger 
children. Wisoff83 also advocated surgery if feasible to 
postpone radiation therapy in young children to limit radi­
ation-induced side effects; however, the usefulness of 
surgery to postpone radiation is also questionable. For 
example, the authors of one study found no advantage to 
partial resection over chemotherapy alone in patients 
younger than 3 years of age.73 in addition, the cognitive 
effects of open craniotomy for tumor must be considered.10
The extent of resection and type of adjuvant therapy do 
not seem to influence PFS or overall survival in patients 
with pilomyxoid astrocytoma compared with survival of 
patients with pilocytic astrocytoma. The less favorable 
prognosis of the pilomyxoid astrocytoma tumor type seems 
related to the pathological features rather than type of treat- 
ment.35
Patients with NF1 represent a different subgroup of pa­
tients with OPGs. Patients with NF1 tend to have more dif­
fuse disease, and surgical intervention tends to fail in them 
at a rate almost twice that of their counterparts without
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F ig . 3. A 5-year-old boy presented with visual loss and hydrocephalus. A CT scan (A) demonstrating a suprasellar 
mass with peripheral rim of calcification suggestive of a craniopharyngioma. Sagittal (B), coronal (C), and axial (D) T1- 
weighted Gd-enhanced MR images demonstrating a brightly enhancing OPG involving the optic chiasm and hypothala­
mus filling the third ventricle. A ventriculoperitoneal shunt was placed for hydrocephalus and chemotherapy was initiat­
ed for the tumor. Coronal (E) and axial (F) MR images obtained 15 months after treatment, showing a decrease in tumor 
size and central enhancement.
NF1.4'13'28'78 In addition, although they may develop sizable 
lesions, the tumors rarely progress after the patient is 6 
years old.23 28 Therefore, surgery is typically not warranted 
in patients with NF1. However, in patients with NF1 who 
have only optic nerve involvement, Jenkin et al.30 reported 
92% survival at 15 years after complete resection. Lesions 
posterior to the chiasm had a much lower relapse-free sur­
vival rate of 41% at 10 years.
Chemotherapy fo r OPGs
Although no single chemotherapeutic agent has been 
identified as primary treatment, chemotherapy is consid­
ered first-line therapy for OPGs that are symptomatic (such 
as visual loss, pituitary dysfunction, and hypothalamic dys­
function). It can treat tumors that have gone beyond the 
observation stage, even in young children, without the 
long-term cognitive and neuroendocrine sequelae seen with
surgery and radiation therapy.7,28 Because of this, che­
motherapy is the primary treatment modality in children 
younger than 3 years of age with progressive or sympto­
matic disease.28 Agents including carboplatin, cisplatin, 
vincristine, vinblastine, actinomycin D, lomustine, thiogua- 
nine, procarbazine, etoposide, tamoxifen, and temozolo- 
mide either as first-line treatment or adjuvant treatment 
have all been used;24,28 however, the most widely used reg­
imen stems from reports published by Packer and col- 
leagues.6162 They treated patients who had newly diagnosed 
low-grade gliomas and patients with recurrent disease. 
Their regimen of concurrent carboplatin and vincristine in 
a 10-week induction phase, followed by 48 weeks of main­
tenance carboplatin/vincristine, resulted in a PFS of 75% at
2 years and 50% at 5 years. In addition, they reported imag­
ing evidence of tumor shrinkage in 63% of patients. Chil­
dren 5 years of age or younger had a notably more favor­
able rate of response.
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F ig . 4. A 9-year-old boy presented with precocious puberty, headaches, and diabetes insipidus. Magnetic resonance 
images reveal a poorly circumscribed, partially hemorrhagic mass centered in the hypothalamus. A and B: Prominent 
seeding of the basilar cisterns is noted. C: A biopsy revealed pilomyxoid astrocytoma.
More recently, Massimino et al.52 reported a 78% PFS 
over 3 years with cisplatin and etoposide, with improved 
visual acuity in most patients and acceptable toxicity pro­
files. Temozolomide has also been shown to be useful in 
stabilizing disease in more than 50% of patients without 
significant toxicity26 and is considered an option in patients 
with progressive OPG in whom first-line therapy has 
failed. Petronio et al.67 addressed the use of a 5-drug regi­
men consisting of 6-thioguanine, procarbazine, dibromod- 
ulcitol, lomustine, and vincristine for treatment of OPG, 
and they obtained favorable results. A similar regimen in 
which dibromodulcitol was excluded was compared with 
the standard regimen of carboplatin and vincristine in 2003 
and was deemed a reasonable second-line therapy for 
patients with OPG.39 Although other chemotherapy regi­
mens have demonstrated efficacy against low-grade gli­
omas, the Packer regimen remains the most commonly 
used course of therapy.3137,50'57'60
Radiotherapy fo r OPGs
In 1956, Taveras et al.77 cited a role for radiation therapy 
for treatment of OPG, based on the results from 34 patients 
treated primarily with radiotherapy. As a result, radiation 
has played a major role in the management of OPGs. Cur­
rently, however, radiation therapy is reserved for treatment 
of progressive OPG in children older than 5-7 years of 
age,45,82 despite the lack of randomized trials comparing 
radiation therapy with other treatment modalities. Authors 
of many studies have demonstrated no benefit of radiation 
therapy over observation or surgery on 10-year progression 
rates, long-term survival, or preservation of sight.15,20,30,69 
However, external-beam radiation therapy has been associ­
ated with good visual outcomes and tumor-free progression 
rates in other series.17,76 In addition, new techniques of de­
livering radiation, including stereotactic radiosurgery and 
proton beam radiotherapy, have been developed.18 Stereo­
tactic conformal radiotherapy has been associated with a 
79% 5-year survival rate without the cognitive or endocrine 
disturbances associated with traditional external-beam ra­
diation therapy.1151,65 Proton beam therapy is an attractive 
option for radiation therapy, as it is able to provide high 
doses of radiation to the lesion with sharp fall-off of ener­
gy within millimeters of the treatment area. In small series, 
it has been found to be well tolerated; however, it is not 
widely available to patients and has not proven to be supe­
rior to standard techniques.27,65 Current recommendations 
state that children younger than 7 years of age should 
receive chemotherapy as first-line treatment. Children be­
tween the ages of 7 and 10 years fit into a gray zone of 
patients who may or may not warrant radiation therapy, and 
patients older than 10 years should be treated with 45-50 
Gy in fractions of 160-200 cGy each.16212628
Prognosis
The natural history of OPGs is highly variable based not 
only on the histological findings but also on the presence or 
absence of NF1 and also differences in each patient. Most 
series investigating this topic have been retrospective, have 
covered large time frames in which treatment modalities 
change, or have involved small numbers of patients be­
cause of the infrequency of the lesion. Overall, however, 
OPGs tend to be low-grade and slow-growing with long 
patient survival.35,65 In addition, the presence of NF1 and an 
anterior location are associated with a more favorable prog- 
nosis,23,80 whereas younger age at presentation is associated 
with a poorer prognosis.2'29'33'59'74'83
Most patients with OPG have an indolent or even 
asymptomatic course. Survival for OPGs confined to the 
optic nerve is close to 100%. Chiasm involvement and par­
ticularly hypothalamic involvement are associated with a 
decreased rate of survival, although survival is still > 90% 
for treated and untreated tumors.65,80 Even patients with pro­
gressive disease have good survival rates.1,8,65 In 2003, Tow 
et al.80 studied the morbidity and mortality rates in a cohort 
of OPG patients with and without NF1, both treated and 
untreated, who were observed for at least 10 years. Most of 
the patients who were not treated had NF1 and survived, 
and they had better visual outcomes than their treated coun- 
terparts.80 This guided the recommendation that OPGs 
should not be treated unless they demonstrate clear disease 
progression. Another argument for observing patients with 
newly diagnosed OPGs is the fact that spontaneous regres­
sion without treatment has been well documented in pa­
tients with and those without NF1.25'48'49'63'65'66
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in a major review of 1136 cases for which treatment data 
were available, Dutton15 found that 40% of patients with 
OPGs of the anterior visual pathway experienced progres­
sion or recurrence. Over a 12-year follow-up period, 33% 
of patients died. The authors of other series have found 
mortality rates up to 50% with 20-year follow-up. in addi­
tion, Dutton found that 21% of patients presented with 
20/40 or better vision and 45% with 20/200 or better vision. 
Accordingly, only 21% of patients experience progressive 
visual loss, and some patients improve.15
For patients with tumor confined to the optic nerve who 
underwent tumor resection, with or without radiation ther­
apy, Dutton15 found a 0% tumor-related mortality rate. Of 
patients with tumor confined to the optic nerve who were 
observed without treatment, 21% exhibited progression, 
5% died of tumor-related causes, and 91% maintained sta­
ble vision.15
Patients with chiasmatic gliomas evaluated in the review 
by Dutton15 demonstrated a 42% rate of progression, 29% 
tumor-related mortality, and a rate of stable visual acuity of 
77%. Treatment did not seem to change these percentages. 
Dutton found that patients who presented with hypothala­
mic or third ventricle involvement fared much worse than 
other patients, especially if hydrocephalus was present. The 
tumor-related mortality rate in this group was 43%, with a 
51% rate of recurrence/progression, although the prognosis 
for vision was similar to that of the chiasmatic tumor group, 
with 71% exhibiting stable vision.15
The subgroup of patients with pilomyxoid astrocytoma 
typically demonstrates a higher rate of local tumor recur­
rence (75% compared with 50%) and CSF dissemination 
(14% compared with 0% in this series) than patients with 
pilocytic astrocytoma.35 In the series by Komotar et al.,35 
overall survival for patients with pilomyxoid astrocytoma 
was 63 months compared with 213 months in patients with 
pilocytic astrocytoma.
Finally, there is some evidence that increased microves­
sel density as a marker of vascularity and angiogenesis is 
associated with shorter PFS in patients with OPGs.6
Conclusions
Optic pathway gliomas are true neoplasms found any­
where along the optic pathway, and they occur primarily in 
children. These tumors are typically slow growing, usually 
present with visual decline that stabilizes over time, and 
can often be observed clinically without treatment. How­
ever, the natural history is often unpredictable. When tumor 
is confined to one optic nerve, surgery is often the treat­
ment of choice. Chemotherapy is first-line treatment for 
most other OPGs, followed by radiation treatment for older 
children with progressive disease. The overall prognosis is 
variable but typically favorable in children with pilocytic 
histology. Patients with pilomyxoid histology may have a 
more aggressive course.
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